z-logo
Premium
Simultaneous LC–MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF
Author(s) -
Thakare Rhishikesh,
Chhonker Yashpal S.,
Gautam Nagsen,
Nelson Amy,
Casaburi Richard,
Criner Gerard,
Dransfield Mark T.,
Make Barry,
Schmid Kendra K.,
Rennard Stephen I.,
Alnouti Yazen
Publication year - 2018
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.4102
Subject(s) - eicosanoid , sputum , chromatography , chemistry , pharmacology , medicine , arachidonic acid , pathology , biochemistry , tuberculosis , enzyme
The differences among individual eicosanoids in eliciting different physiological and pathological responses are largely unknown because of the lack of valid and simple analytical methods for the quantification of individual eicosanoids and their metabolites in serum, sputum and bronchial alveolar lavage fluid (BALF). Therefore, a simple and sensitive LC–MS/MS method for the simultaneous quantification of 34 eicosanoids in human serum, sputum and BALF was developed and validated. This method is valid and sensitive with a limit of quantification ranging from 0.2 to 3 ng/mL for the various analytes, and has a large dynamic range (500 ng/mL) and a short run time (25 min). The intra‐ and inter‐day accuracy and precision values met the acceptance criteria according to US Food and Drug Administration guidelines. Using this method, detailed eicosanoid profiles were quantified in serum, sputum and BALF from a pilot human study. In summary, a reliable and simple LC–MS/MS method to quantify major eicosanoids and their metabolites was developed and applied to quantify eicosanoids in human various fluids, demonstrating its suitability to assess eicosanoid biomarkers in human clinical trials.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here